Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05659719 · ClinicalTrials.gov registry record
A Study to Learn About Recifercept in Patients With Achondroplasia
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 248
- Enrollment target
NCT05659719: Completed study, sponsored by Pfizer.
NCT05659719 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 248 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05659719 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 248 participants
- Enrollment target
Study Summary
The purpose of this study is to learn about the study medicine (called recifercept) in people with achondroplasia. Achondroplasia is a very rare disease and patients of achondroplasia have short arms and legs. The study will include data already collected from a recifercept clinical trial and data collected from a separate study of achondroplasia. This study will compare patient experiences and will help the investigators determine if the study medicine, recifercept, is effective.
Primary Outcome
Height growth was defined as ratio of observed change from baseline in standing height (centimeter) to expected change from baseline (centimeter) in reference population. For C4181001 cohort, baseline value was defined as the value recorded at the date of informed consent, whereas for C4181005 cohort the baseline value was the value taken at Day 1 before dosing.
Interventions
- OTHER Recifercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2022-10-19 |
| Est. Completion | 2023-05-16 |
What the finished NCT05659719 record still lists
NCT05659719 is an observational study that tracks outcomes without assigning an intervention. The registered 248 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Recifercept is the first listed.
NCT05659719 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05659719 about?
NCT05659719 is a clinical study titled "A Study to Learn About Recifercept in Patients With Achondroplasia". The purpose of this study is to learn about the study medicine (called recifercept) in people with achondroplasia. Achondroplasia is a very rare disease and patients of achondroplasia have short arms and legs. The study will include data already collected from a recifercept clinical trial and data c...
What is the current status of trial NCT05659719?
This trial is currently completed. The enrollment target is 248 participants. The study started on 2022-10-19. Estimated completion is 2023-05-16.
What interventions are being tested in trial NCT05659719?
The interventions under investigation include: Recifercept (OTHER).
Who is sponsoring clinical trial NCT05659719?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04577911 · 248 participants
How is Social Connection Represented in the Brain?
- NCT04777994 · 248 participants · Phase 1
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- NCT04792489 · 248 participants · Phase 2
DALY II USA/ MB-CART2019.1 for DLBCL
- NCT04830137 · 248 participants · Phase 1
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI